Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage biopharmaceutical company, reported a net loss of $137.1 million for FY 2025 ending December 31, 2025, an improvement from $165.9 million in FY 2024, driven by reduced operating expenses following a January 2025 strategic restructuring that cut workforce by 40% and prioritized azenosertib development. Revenues from licensing and sales of intellectual property were $0 in 2025, down from $67.4 million in 2024 due to one-time Immunome transactions. Total operating expenses fell 41% to $152.8 million, with R&D at $107.3 million (vs. $167.8 million) and G&A at $37.7 million (vs. $87.1 million), including $7.8 million restructuring costs. Loss from operations narrowed to $152.8 million from $191.2 million. Investment income declined to $16.2 million from $25.5 million. Balance sheet shows $289.0 million total assets, $253.2 million current assets including $36.0 million cash and $209.9 million marketable debt securities, $72.8 million liabilities, and $216.2 million stockholders' equity. Cash used in operations was $125.2 million, with $131.6 million provided by investing. Cash runway extends into late 2027, supporting DENALI Part 2 topline by end-2026 and ASPENOVA Phase 3 initiation in H1 2026, key to potential accelerated approval in Cyclin E1-positive PROC.

Key Takeaways